Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: von Willebrand disease".)

International

●International Society on Thrombosis and Haemostasis (ISTH): Guidance on the diagnosis and management of platelet type von Willebrand disease (2020)

●International consensus report on the investigation and management of primary immune thrombocytopenia, update (2019)

●ISTH: Guidance for the management of cancer-associated thrombosis in patients with thrombocytopenia (2018)

●AABB: Clinical practice guideline for platelet transfusion (2015)

●ISTH: Recommendations and guideline for standardization of laboratory testing for drug-induced immune thrombocytopenia (2015)

●ISTH: Recommendations and guidelines for diagnosis of inherited platelet function disorders (2015)

●Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenic purpura of adults and children – Report from an international working group (2009)

Canada

●Choosing Wisely Canada: Don't give IVIG as first line treatment for patients with asymptomatic immune thrombocytopenia (ITP) (updated 2021)

●Choosing Wisely Canada: Don't routinely transfuse platelets for patients with chemotherapy-induced thrombocytopenia if the platelet count is greater than 10 X 109/L in the absence of bleeding (updated 2020)

●Canadian Paediatric Society (CPS): Practice point on the diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood (2018, updated 2020)

United States

●American College of Obstetricians and Gynecologists (ACOG): Practice bulletin on thrombocytopenia in pregnancy (2019)

●American Society of Hematology (ASH): Guidelines for immune thrombocytopenia (2019)

●ASH: Management of immune thrombocytopenia (ITP) – A pocket guide for the clinician (2019)

●ASH: Clinical practice guide on thrombocytopenia in pregnancy – Quick reference (2013)

Europe

●European Haematology Association (EHA): Guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer (2022)

●European Society for Blood and Marrow Transplantation (EBMT): Immune thrombocytopenia – A practical guide for nurses and other allied healthcare professionals (2011)

United Kingdom

●British Society for Haematology (BSH): Guideline on clinical and laboratory diagnosis of heritable platelet disorders in adults and children (2021)

●BSH: Good practice paper for the prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids (2019)

●BSH: Guidelines for the use of platelet transfusions (2016)

●Choosing Wisely UK: Royal College of Pathologists – Only consider transfusing platelets for patients with chemotherapy-induced thrombocytopenia where the platelet count is <10 x 109/L except when the patient has clinical significant bleeding or will be undergoing a procedure with a high risk of bleeding (2016)

Australia–New Zealand

●Choosing Wisely Australia: Do not treat patients with immune thrombocytopenic purpura (ITP) in the absence of bleeding or a platelet count <30,000/L without risk factors for bleeding

Japan

●[In Japanese] Japanese Society of Hematology (JSH): Current management of primary immune thrombocytopenia in Japan (2013)